Related Experiment Video

Updated: May 25, 2026

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta
08:08

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta

Published on: June 10, 2015

TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and

Anookh Mohanan1, Ram Gupta, Amita Dubey

  • 1Torrent Research Centre, Torrent Pharmaceuticals Ltd., Gujarat, Gandhinagar 382428, India.

International Journal of Hypertension
|January 12, 2012
PubMed

Insights

A novel dual angiotensin II/endothelin receptor blocker, TRC120038, effectively lowered blood pressure and protected against kidney and heart damage in hypertensive rats. This compound shows promise for treating complex cardiovascular and renal conditions.

Area of Science:

  • Cardiovascular Pharmacology
  • Renal Physiology
  • Hypertension Research

Background:

  • Angiotensin II and endothelin pathways are critical in elevating blood pressure and causing end-organ damage in hypertensive individuals.
  • Obese Zucker spontaneously hypertensive fatty rats (ob-ZSF1) serve as a relevant model for studying moderate hypertension, diabetes, and associated renal and cardiac dysfunction.

Purpose of the Study:

  • To evaluate the efficacy of TRC120038, a novel dual AT(1)/ET(A) receptor blocker, in reducing blood pressure and mitigating organ damage.
  • To compare the effects of TRC120038 with candesartan cilexetil in the ob-ZSF1 rat model.

Main Methods:

  • Ob-ZSF1 rats were administered TRC120038, candesartan cilexetil, or vehicle control with a 0.5% salt load.
  • Blood pressure was continuously monitored using radio-telemetry.
  • Renal function markers and cardiac function were assessed, with terminal histopathological evaluation for renal changes.

Main Results:

  • TRC120038 demonstrated a superior reduction in both systolic and diastolic blood pressure compared to candesartan at its maximal antihypertensive dose.
  • Treatment with TRC120038 significantly reduced the severity of renal dysfunction.
  • TRC120038 effectively preserved cardiac function in the ob-ZSF1 rat model.

Conclusions:

  • TRC120038 exhibits potent antihypertensive effects superior to candesartan in a model of complex hypertension.
  • This dual-acting receptor blocker offers significant renoprotective and cardioprotective benefits.
  • TRC120038 represents a promising therapeutic agent for managing hypertension with associated diabetes and organ damage.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Modified Heterotopic Abdominal Heart Transplantation and a Novel Aortic Regurgitation Model in Rats13:32

Modified Heterotopic Abdominal Heart Transplantation and a Novel Aortic Regurgitation Model in Rats

Published on: June 2, 2023

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...